scholarly journals Diagnosing empty iron stores in women: unbound iron binding capacity (UIBC) versus soluble transferrin receptor (sTFR)

2021 ◽  
pp. 1-5
Author(s):  
Arne Åsberg ◽  
Ketil Thorstensen ◽  
Gunhild Garmo Hov ◽  
Ann Elisabeth Åsberg
Keyword(s):  
Transferrin Receptor ◽  
Binding Capacity ◽  
Iron Binding ◽  
Soluble Transferrin Receptor ◽  
Iron Stores ◽  
Iron Binding Capacity

scholarly journals The importance of iron metabolism, hepcidine and soluble transferrin receptor in pathogenesis of anemia in patients with solid tumors

2018 ◽  
Vol 20 (3) ◽  
pp. 91-94
Author(s):  
A V Gordienko ◽  
V T Sakhin ◽  
E V Kryukov ◽  
A V Sotnikov ◽  
O A Rukavitsyn
Keyword(s):  
Transferrin Receptor ◽  
Binding Capacity ◽  
Total Iron ◽  
Malignant Neoplasms ◽  
Iron Binding ◽  
Total Iron Binding Capacity ◽  
Soluble Transferrin Receptor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Iron Binding Capacity

A comparative analysis of hemogram parameters, iron metabolism, C-reactive protein, hepcidin, soluble transferrin receptor in patients with malignant neoplasms, accompanied by anaemia and without it. Patients with anaemia compared with non-anaemic patients had lower haemoglobin, erythrocyte, hematocrit, mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration, iron, iron transferrin saturation, total iron-binding capacity, and higher levels C-reactive protein, hepcidin, soluble transferrin receptor (p0,05). Negative correlations of moderate strength between hepcidin and erythrocyte levels (r=-0,41), hemoglobin (r=-0,3), hematocrit (r=-0,35), and total iron-binding capacity (r=-0,51) and transferrin (r=-0,54). In addition, negative correlations of moderate strength were revealed between the soluble transferrin receptor and hemoglobin level (r=-0,57), hematocrit (r -0,49), iron transferrin saturation (r=-0,47), mean corpuscular hemoglobin (r=-0,44), mean corpuscular volume (r=-0,39). A direct correlation of moderate strength was found between the soluble transferrin receptor and transferrin (r=0,41) and total iron-binding capacity (r=0,38), as well as between hepcidin and ferritin (r=0,61), C-reactive protein (r=0,48). In general, the development of functional iron deficiency in patients with anaemia and malignant neoplasms has been established, and the value of hepcidin and soluble transferrin receptor in the genesis of this anaemia has been confirmed.

Iron preparations for children

1966 ◽  
Vol 4 (3) ◽  
pp. 9-11
Keyword(s):  
Bone Marrow ◽  
Iron Deficiency ◽  
Blood Smear ◽  
Binding Capacity ◽  
Iron Binding ◽  
Iron Stores ◽  
Plasma Iron ◽  
Hypochromic Anaemia ◽  
Iron Binding Capacity

We have discussed iron preparations for adults in earlier articles;1 much of the information applies equally to children. Iron is not a ‘tonic’ and should be given only to prevent or correct iron deficiency. Estimation of the haemoglobin and inspection of a blood smear are the minimum investigations necessary before iron is prescribed in therapy. When deficiency is suspected in the absence of hypochromic anaemia, plasma iron and iron-binding capacity should be estimated and/or the bone marrow examined for haemosiderin crystals which disappear when iron stores are depleted.

Transferrin Types, Iron-Binding Capacity and Body Iron Stores

1993 ◽  
Vol 43 (6) ◽  
pp. 337-341 ◽  
Author(s):  
C. Sikström ◽  
L. Beckman ◽  
G. Hallmans ◽  
K. Asplund
Keyword(s):  
Binding Capacity ◽  
Iron Binding ◽  
Body Iron ◽  
Iron Stores ◽  
Iron Binding Capacity

Lab Indicators of Iron Level in Bone Marrow Aspirate of Patients Diagnosed with Multiple Myeloma

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5397-5397
Author(s):  
Ankit Mangla ◽  
Sriman Swarup ◽  
Muhammad Umair Mushtaq ◽  
Hussein Hamad ◽  
Sharad Khurana ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Iron Deficiency ◽  
Bone Marrow Aspirate ◽  
Binding Capacity ◽  
Iron Level ◽  
Iron Binding ◽  
Iron Stores ◽  
Bone Marrow Iron ◽  
Iron Binding Capacity

Abstract Introduction Iron plays a critical role in patients with multiple myeloma (MM). The limited availability of iron to the developing erythroid precursors results in the characteristic anemia so frequently seen in these patients. Moreover, iron is also a determinant in growth of the malignant plasma cells that makes it one of the critical factors in progression of the disease. Iron is a key component in success of erythropoietin (EPO) therapy that is often used to maintain hemoglobin (Hb) level of >10g/dL in patients with MM. International Myeloma working group (2011) advised transfusing IV iron to aid in success of EPO therapy. However, apart from determining the iron stores on bone marraow aspirate, there is hardly any reliable clinical or lab indicator of the iron stores in the body. The utility of various iron indices in determining the bone marrow iron stores remains anecdotal. In this study we aim to determine the relation between iron indices and iron level in the bone marrow of patients diagnosed with multiple myeloma. Methods A total of 268 multiple myeloma patients, diagnosed from 2004 to 2015, were identified from tumor registry of John H. Stroger Jr. Hospital of Cook County, Chicago. Accuracy of ferritin, iron level, total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC) and transferrin saturation (TSAT) was evaluated using receiver operating characteristic curves (ROC). Out of sampled patients, 167 patients had a concurrent bone marrow biopsy and aspirate, serum ferritin and iron panel, and were included in ROC analyses. Results The study population consisted of 57% African-Americans, 18% Caucasians and 16% Hispanics. Median age was 61 years and 51% were females. Past history was significant for hypertension (48%), diabetes (31%), co-existing inflammatory conditions (18%), smoking (25%), alcohol abuse (17%) and illicit drug abuse (8%). Median hemoglobin, mean corpuscular volume (MCV), leukocytes and platelets were 10g/dL, 90.3fL, 6,200/mcL and 219,500/mcL respectively. Bone marrow aspirates for iron were rated as absent (37%), mild/moderate (18%) and adequate/normal (45%). Anemia was found in 79% of males (Hb <12.9g/dL) and 76% of females (Hb<11.7 g/dL). Of the patients with anemia, 36% of males and 39% of females had absent iron stores (determined by prussian blue staining method) on bone marrow aspirate. MCV was not significantly related with iron deficiency. Iron level, TIBC, UIBC and TSAT were not significantly associated with bone marrow iron (P>0.05). Only ferritin was significant predictor of iron deficiency and presence of iron in bone marrow (AUC 0.64, 95%CI 0.55-0.74, P=0.002). Ferritin levels of ≤15mcg/L (positive LR 3.77, sensitivity 3.4%, specificity 99.1%), ≤30mcg/L (positive LR 2.59, sensitivity 11.9%, specificity 95.4%) and ≤50mcg/L (positive LR 4.35, sensitivity 32.2%, specificity 92.6%) predicted iron deficiency. Ferritin levels of ≥100mcg/L (positive LR 1.47, sensitivity 76.9%, specificity 47.5%), ≥200mcg/L (positive LR 1.46, sensitivity 54.6%, specificity 62.7%) and ≥500mcg/L (positive LR 1.94, sensitivity 23.1%, specificity 88.1%) ruled out iron deficiency. Conclusion Of all the indices predicting iron deficiency, only ferritin was significantly associated with absent iron in bone marrow aspirates. In MM patients, iron supplementation should be considered with ferritin levels of ≤50mcg/L and can be deferred with ferritin levels of ≥500mcg/L. Further studies are needed to explore the association. Disclosures No relevant conflicts of interest to declare.

scholarly journals Soluble transferrin receptor in sickle cell diseases: correlation with spleen function

1999 ◽  
Vol 117 (4) ◽  
pp. 145-150 ◽  
Author(s):  
Helena Zerlotti Wolf Grotto ◽  
Elza Miyuki Kimura ◽  
Márcia Victor Carneiro
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Transferrin Receptor ◽  
Binding Capacity ◽  
Inverse Correlation ◽  
Tertiary Hospital ◽  
University Hospital ◽  
Soluble Transferrin Receptor ◽  
Normal Individuals ◽  
Iron Binding Capacity

OBJECTIVE: To correlate spleen function with soluble transferrin receptor (sTfR) levels and red cell ferritin (RCF) values in patients with sickle cell diseases. DESIGN: Prospective study. LOCATION: University Hospital, School of Medical Sciences, State University of Campinas; a tertiary hospital. PARTICIPANTS: 60 patients with sickle cell diseases, in a steady state, who had not received blood transfusions for 3 months; 28 normal individuals with no clinical or laboratory signs of anemia. MEASUREMENTS: Determination of serum iron, transferrin iron-binding capacity, serum ferritin, RCF and sTfR. Evaluation of spleen function: erythrocytes with pits were quantified. RESULTS: Patients with sickle cell anemia had sTfR levels significantly higher than in normal individuals or those with HbSC (p=0.0001) and there was an inverse correlation between sTfR and fetal Hb (p=0.0016). RCF values were significantly higher in sickle cell anemia patients than in normal individuals or those with HbSC (p=0.0001), and there was a correlation between RCF and pitted erythrocytes (p=0.0512). CONCLUSION: The association between sTfR and fetal Hb confirms the contribution of fetal Hb to improving the hemolytic state by minimizing the consequent reactive erythrocyte expansion. High sTfR levels are not related to the degree of spleen function deficiency seen in sickle cell disease patients. The deficiency in the exocytosis process of the spleen occurring in sickle cell anemia patients may contribute to their accumulation of RCF.

Sign in / Sign up

Export Citation Format

Share Document